Literature DB >> 6857145

Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia.

M Cazzola, C Borgna-Pignatti, P de Stefano, G Bergamaschi, I G Bongo, L Dezza, F Avato.   

Abstract

Liver and spleen iron concentrations, serum ferritin level and binding of S-ferritin to concanavalin A (Con A) were measured in 12 patients with thalassaemia major or intermedia at the time of splenectomy. All these subjects had increased liver iron concentration, most of them had hepatic fibrosis but none of them had histological evidence of chronic hepatitis. No patient had ascorbic acid deficiency. Serum ferritin concentration was increased in all cases, ranging from 266 to 5504 micrograms/l. In all but 2 subjects most of the protein did not bind to Con A, thus behaving as tissue ferritin. There were highly significant correlations between serum ferritin concentration, amount of blood transfused and liver iron concentration. On the average, iron concentration in the liver was about 3 times that in the spleen. The findings obtained suggest that in patients with thalassaemia major or intermedia most of the iron is deposited in parenchymal tissues and most of the S-ferritin derives by leakage from the cytosol of iron-loaded parenchymal cells. S-ferritin is a valid index of liver iron overload in thalassaemic patients without complications such as viral hepatitis and/or ascorbic acid deficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6857145     DOI: 10.1111/j.1600-0609.1983.tb01494.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  9 in total

1.  Follow-up study of thyroid function in polytransfused thalassemic patients.

Authors:  M Maggiolini; G De Luca; M Bria; D Sisci; S Aquila; V Pezzi; M Lanzino; A Giorno; O Tamburrini; M Della Sala; E Corcioni; C Brancati; S Ando
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

2.  Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease.

Authors:  S Vignes; G Le Moël; B Fautrel; B Wechsler; P Godeau; J C Piette
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

3.  Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice.

Authors:  Qi Feng; Mary C Migas; Abdul Waheed; Robert S Britton; Robert E Fleming
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-19       Impact factor: 4.052

4.  Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis.

Authors:  T Güngör; E Rohrbach; E Solem; J P Kaltwasser; B Kornhuber
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

5.  Quantitative T2* MRI for bone marrow iron overload: normal reference values and assessment in thalassemia major patients.

Authors:  Antonella Meloni; Laura Pistoia; Gennaro Restaino; Massimiliano Missere; Vincenzo Positano; Anna Spasiano; Tommaso Casini; Antonella Cossu; Liana Cuccia; Antonella Massa; Francesco Massei; Filippo Cademartiri
Journal:  Radiol Med       Date:  2022-09-10       Impact factor: 6.313

Review 6.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30

7.  Association between iron deposition in splenic,hepatic and myocardial tissues assessed by T2* relaxometry technique.

Authors:  Ali Mohammadzadeh; Saeed Alizadeh; Layla Shojaie; Maryam Mohammadzadeh
Journal:  Caspian J Intern Med       Date:  2021

Review 8.  The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.

Authors:  Athanassios Aessopos; Vasilios Berdoukas; Maria Tsironi
Journal:  Eur J Haematol       Date:  2007-12-10       Impact factor: 2.997

9.  Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Authors:  Renzo Galanello
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.